Annals of Oncology

Annals of Oncology Journal

Publication venue for

Multicenter, randomized, parallel group, phase II study to establish the efficacy and safety of CBP501, cisplatin, and nivolumab for I third-line treatment of patients with exocrine pancreatic cancer and WBC <10,000/mm3. 34:S900-S900. 2023
Pancreatic cancer oral inverse agonist of RORgT receptor targets primary cancer cells and alters inflammatory mediators of the tumor microenvironment. 34:S157-S157. 2023
Phase II clinical trial: Safety and efficacy study of tocilizumab (Toci) in combination with ipilimumab (Ipi) 3mg/kg plus nivolumab (Nivo) 1mg/kg in patients (pts) with metastatic melanoma (MM). 33:S923-S923. 2022
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. 32:S1403-S1403. 2021
Preliminary results from PROPEL: A phase I/II study of bempegaldesleukin (BEMPEG: NKTR-214) plus pembrolizumab (PEMBRO) with or without chemotherapy in patients with metastatic NSCLC. 32:S1438-S1440. 2021
A phase I dose escalation study of PRS-343, a HER2/4-1BB bispecific molecule, in patients with HER2-positive malignancies. 31:S462-S463. 2020
ENTRATA: Randomized, double-blind, phase II study of telaglenastat (tela; CB-839) + everolimus (E) vs placebo (pbo) plus E in patients (pts) with advanced/metastatic renal cell carcinoma (mRCC). 30:889. 2019
Safety and efficacy of the oral CXCR4 inhibitor X4P-001+axitinib in advanced renal cell carcinoma patients: An analysis of subgroup responses by prior treatment. 30. 2019
A phase IIa trial to assess the safety and efficacy of BL-8040 and pembrolizumab in patients with metastatic pancreatic adenocarcinoma (PDAC). 29. 2018
The commonwealth neuroendocrine tumour collaboration (CommNETs) and North American neuroendocrine tumor society (NANETS) endorsement and update of European neuroendocrine tumor society (ENETS) best practice consensus for lung neuroendocrine tumors (LNET). 29. 2018
Interim safety results from the phase 2 ABOUND.PS2 study evaluating nab-paclitaxel (nab-P) plus carboplatin (C) followed by nab-P monotherapy in patients (pts) with NSCLC and an Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2. 27. 2016

International Standard Serial Number (ISSN)

0923-7534